≡

Multiplex Assay Kit for Noggin (NOG) ,etc. by FLIA (Flow Luminescence Immunoassay)

SYM1; SYNS1; Synostoses(Multiple)Syndrome 1; Symphalangism 1(Proximal)

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity for detection of Noggin (NOG) ,etc. by FLIA (Flow Luminescence Immunoassay).
100% cross-reactivity of Noggin (NOG) ,etc. by FLIA (Flow Luminescence Immunoassay) was observed among Human, Mouse, Rat.

Recovery

Matrices listed below were spiked with certain level of recombinant Noggin (NOG) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Noggin (NOG) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 81-92 88
EDTA plasma(n=5) 91-99 94
heparin plasma(n=5) 88-105 94

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Noggin (NOG) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Noggin (NOG) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Noggin (NOG) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 81-90% 91-101% 92-104% 81-101%
EDTA plasma(n=5) 79-101% 96-103% 79-104% 80-88%
heparin plasma(n=5) 81-90% 94-101% 79-95% 96-104%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:NOG) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Arthritis Rheumatol Imbalance between BMP2 and Noggin induces abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis PubMed: 26413886
Arthritis Rheumatol.  Imbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal Osteogenic Differentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis Pubmed:26413886
Clin Exp Pharmacol Physiol. Oxygen-glucose deprivation preconditioning protects neurons against oxygen-glucose deprivation/reperfusion induced injury via bone morphogenetic protein-7 mediated ERK, p38 and Smad signalling pathways. Pubmed:26385023
European cells & materials The BMP2 variant L51P restores the osteogenic differentiation of human mesenchymal stromal cells in the presence of intervertebral disc cells. pubmed:28266688
Arthritis & Rheumatology mbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal OsteogenicDifferentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis. pubmed:26413886
Biotechnology and Applied Biochemistry The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cells. pubmed:28981962
Heliyon Efficient in vitro delivery of Noggin siRNA enhances osteoblastogenesis pubmed:29167826
Journal of Cellular Biochemistry Low‐intensity pulsed ultrasound promotes bone morphogenic protein 9‐induced osteogenesis and suppresses inhibitory effects of inflammatory cytokines on cellular … Pubmed: 31006911
Aging Male Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment Pubmed: 32160825
J Reconstr Microsurg Effect of Simvastatin Use in Free Tissue Transfer: An Experimental Study in a Rat Epigastric Free Flap Model Pubmed: 31995818
Biochem Biophys Rep Slow diffusion on the monolayer culture enhances auto/paracrine effects of Noggin in differentiation of human iPS cells induced by BMP Pubmed:35005256
Catalog No. Related products for research use of Homo sapiens (Human), Mus musculus (Mouse), Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
SEC130Mi ELISA Kit for Noggin (NOG) Enzyme-linked immunosorbent assay for Antigen Detection.
HEC130Mi High Sensitive ELISA Kit for Noggin (NOG) Enzyme-linked immunosorbent assay for Antigen Detection.
LMC130Mi Multiplex Assay Kit for Noggin (NOG) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.